MiRNA-based therapy for Pulmonary Hypertension (PAH): MiRNA-99 inhibits pulmonary hypertension via induction of PDLIM5, 14/February/2015, 23.22

Natural product-based therapy for cancer: Tumor suppressor p53 homologues p73 and p63 suppress the expression of oncoprotein Mcl-1 and increase the expression of proapoptotic protein BIM via down regulation of their target genes, 14/February/2015, 23.17
February 14, 2015
Small molecule-based Regenerative Stem cell therapy for Myocardial Infarction: Paracetamol (4-Hydroxyacetanilide) improves ageing- and stress-associated decline in cardiac function via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 14/February/2015, 23.40
February 14, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Significance: This study suggests, for the first time, that MiRNA-99 may increase the expression of PDLIM5. Thereby, it may inhibit pulmonary hypertension. Together, pharmacological formulations encompassing “MiRNA-99 activators may be used to treat pulmonary arterial hypertension (PAH).

Amount: $ 300*

Undisclosed information: How miR-99 increases the expression of PDLIM5

To citeBoominathan, MiRNA-based therapy for Pulmonary Hypertension (PAH): MiRNA-99 inhibits pulmonary hypertension via induction of PDLIM5, 14/February/2015,  23.22,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.